Pemetrexed in the treatment of advanced non-squamous lung cancer

Lung Cancer

Volumn 66, Issue 2, 2009, Pages 141-149

  Rossi, Antonio ^a   Ricciardi, Serena ^b   Maione, Paolo ^a   de Marinis, Filippo ^b   Gridelli, Cesare ^a  

^a S G MOSCATI HOSPITAL   (Italy)

^b SAN CAMILLO FORLANINI HOSPITAL   (Italy)

Author keywords

First line therapy; Maintenance therapy; Non squamous carcinoma; NSCLC; Pemetrexed; SCLC; Second line therapy

Indexed keywords

BEVACIZUMAB; CARBOPLATIN; CETUXIMAB; CISPLATIN; DOCETAXEL; ENZASTAURIN; ETOPOSIDE; FOLIC ACID; GEMCITABINE; NAVELBINE; OXALIPLATIN; PEMETREXED; PLACEBO;

ADVANCED CANCER; ALOPECIA; ANEMIA; BLOOD TOXICITY; CANCER CHEMOTHERAPY; CANCER RECURRENCE; CANCER RELAPSE; CANCER SURVIVAL; CLINICAL TRIAL; DOSAGE SCHEDULE COMPARISON; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENTIATION; DRUG SAFETY; DYSPNEA; FATIGUE; FEBRILE NEUTROPENIA; HUMAN; HYPERTENSION; INFECTION; LARGE CELL CARCINOMA; LEUKOPENIA; LOADING DRUG DOSE; LUNG ADENOCARCINOMA; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; LUNG SQUAMOUS CELL CARCINOMA; LYMPHOCYTOPENIA; MAINTENANCE THERAPY; MALIGNANT MESOTHELIOMA; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; PLEURA MESOTHELIOMA; PRIORITY JOURNAL; RASH; REVIEW; SIDE EFFECT; THROMBOCYTOPENIA; THROMBOSIS; TREATMENT OUTCOME; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; VEIN THROMBOSIS; VITAMIN SUPPLEMENTATION;

ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BIOLOGICAL PRODUCTS; CARCINOMA, NON-SMALL-CELL LUNG; CISPLATIN; CLINICAL TRIALS AS TOPIC; DEOXYCYTIDINE; FOLIC ACID ANTAGONISTS; GLUTAMATES; GUANINE; HUMANS; LUNG NEOPLASMS; SMALL CELL LUNG CARCINOMA;

EID: 70350085828     PISSN: 01695002     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lungcan.2009.06.006     Document Type: Review

References (59)

1. Jemal A., Siegel R., Ward E., Hao Y., Xu J., Murray T., et al. Cancer statistics. CA Cancer J Clin 58 (2008) 71-96
2. Parkin D.M., Bray F., Ferlay J., and Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 55 (2005) 74-108
3. Schiller J.H., Harrington D., Belani C.P., Langer C., Sandler A., Krook J., et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 346 (2002) 92-98
4. Sandler A., Gray R., Perry M.C., Brahmer J., Schiller J.H., Dowlati A., et al. Paclitaxel-carboplatin alone or with bevacizumab for non small cell lung cancer. N Engl J Med 355 (2006) 2542-2550
5. Reck M., von Pawel J., Zatloukal P., Ramlau R., Gorbounova V., Hirsh V., et al. Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAil. J Clin Oncol 27 (2009) 1227-1234
6. Manegold C., von Pawel J., Zatloukal P., Ramlau R., Gorbounova V., Hirsh V., et al. BO17704 (AVAIL): a phase II randomised study of first-line bevacizumab combined with cisplatin/gemcitabine (CG) in patients (PTS) with advanced or recurrent non-squamous, non-small cell lung cancer (NSCLC). Ann Oncol 19 Suppl. 8 (2008) viii1 [abstract LBA1]
7. Johnson D.H., Fehrenbacher L., Novotny W.F., Herbst R.S., Nemunaitis J.J., Jablons D.M., et al. Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol 22 (2004) 2184-2191
8. Shepherd F.A., Pereira J.R., Ciuleanu T., Tan E.H., Hirsh V., Thongprasert S., et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 353 (2005) 123-132
9. Scagliotti G., Hanna N., Fossella F., Sugarman K., Blatter J., Peterson P., et al. The differential efficacy of pemetrexed according to NSCLC histology: a review of two phase III studies. Oncologist 14 (2009) 253-263
10. Shih C., Chen V.J., Gossetti L.S., Gates S.B., MacKellar W.C., Habeck L.L., et al. LY231514, a pirrolo[2,3-d]pyrimidine-based antifolate that inhibits multiple folate requiring enzymes. Cancer Res 57 (1997) 1116-1123
11. Schultz R.M., Chen V.J., Bewley J.R., Roberts E.F., Shih C., and Dempsey J.A. Biological activity of the multitargeted antifolate, MTA (LY231514), in human cell lines with different resistance mechanisms to antifolate drugs. Sem Oncol 26 Suppl. 6 (1999) 68-73
12. Ceppi P., Volante M., Saviozzi S., Rapa I., Novello S., Cambieri A., et al. Squamous cell carcinoma of the lung compared with other histotypes shows higher messenger RNA and protein levels for thymidylate synthetase. Cancer 107 (2006) 1589-1596
13. Scagliotti G., Monica V., Ceppi P., Righi L., Cambieri A., Volante M., et al. Baseline thymidylate synthetase expression according to histological subtypes of non-small cell lung cancer. J Clin Oncol 27 15S (2009) 387s [abstract 7521]
14. Huang C.L., Liu D., Nakano J., Yokomise H., Ueno M., Kadota K., et al. E2F1 overexpression correlates with thymidylate synthase and survivin gene expressions and tumor proliferation in non small-cell lung cancer. Clin Cancer Res 13 (2007) 6938-6946
15. Salon C., Merdzhanova G., Brambilla C., Brambilla E., Gazzeri S., and Eymin B. E2F-1, Skp2 and cyclin E oncoproteins are upregulated and directly correlated in high-grade neuroendocrine lung tumors. Oncogene 26 (2007) 6927-6936
16. Hanauske A.R., Eismann U., Oberschmidt O., Pospisil H., Hoffmann S., Hanauske-Abel H., et al. In vitro chemosensitivity of freshly explanted tumor cells to pemetrexed is correlated with target gene expression. Invest New Drugs 25 (2007) 417-423
17. Niyikiza C., Baker S.D., Seitz D.E., Walling J.M., Nelson K., Rusthoven J.J., et al. Homocysteine and methylmalonic acid: markers to predict and avoid toxicity from pemetrexed therapy. Mol Cancer Ther 1 (2002) 545-552
18. Chattopadhyay S., Tamari R., Min S.H., Zhao R., Tsai E., and Goldman I.D. Commentary: a case for minimizing folate supplementation in clinical regimens with pemetrexed based on the marked sensitivity of the drug to folate availability. Oncologist 12 (2007) 808-815
19. Vogelzang N.J., Rusthoven J.J., Symanowski J., Denham C., Kaukel E., Ruffie P., et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol 21 (2003) 2636-2644
20. Hanna N., Shepherd F.A., Fossella F.V., Pereira J.R., De Marinis F., von Pawel J., et al. Randomized phase III trial of pemetrexed versus docetaxel in patients with non small cell lung cancer previously treated with chemotherapy. J Clin Oncol 22 (2004) 1589-1597
21. Scagliotti G., Parikh P., von Pawel J., Biesma B., Vansteenkiste J., Manegold C., et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage NSCLC. J Clin Oncol 26 (2008) 3543-3551
22. Cullen M.H., Zatloukal P., Sorenson S., Novello S., Fischer J.R., Joy A.A., et al. A randomized phase III trial comparing standard and high dose pemetrexed as second-line treatment in patients with locally advanced or metastatic non-small cell lung cancer. Ann Oncol 19 (2008) 939-945
23. Ohe Y., Ichinose Y., Nakagawa K., Tamura T., Kubota K., Yamamoto N., et al. Efficacy and safety of two doses of pemetrexed supplemented with folic acid and vitamin B12 in previously treated patients with non-small cell lung cancer. Clin Cancer Res 14 (2008) 4206-4212
24. Peterson P., Park K., Fossella F., Gatzemeier U., John W., and Scagliotti G. Is pemetrexed more effective in adenocarcinoma and large cell lung cancer than in squamous cell carcinoma? A retrospective analysis of a phase III trial of pemetrexed vs. docetaxel in previously treated patients with advanced non-small cell lung cancer (NSCLC). J Thorac Oncol 2 Suppl. 4 (2007) S851 [abstract P2-328]
25. Smit E.F., Burgers S.A., Biesma B., Smit H.J., Eppinga P., Dingemans A.M., et al. Randomized phase II and pharmacogenetic study of pemetrexed compared with pemetrexed plus carboplatin in pretreated patients with advanced non-small-cell lung cancer. J Clin Oncol 27 (2009) 2038-2045
26. Rusthoven J.J., Eisenhauer E., Butts C., Gregg R., Dancey J., Fisher B., et al. Multitargeted antifolate LY2311514 as first line chemotherapy for patients with advanced non small cell lung cancer: a phase II study. J Clin Oncol 17 (1999) 1194-1199
27. Clarke S.J., Abratt R., Goedhals L., Boyer M.J., Millward M.J., and Ackland S.P. Phase II trial of pemetrexed disodium (ALIMTA, LY231514) in chemotherapy-naive patients with advanced non small cell lung cancer. Ann Oncol 13 (2002) 737-741
28. Gridelli C., Kaukel E., Gregorc V., Migliorino M.R., Muller T.R., Manegold C., et al. Single-agent pemetrexed or sequential pemetrexed/gemcitabine as front-line treatment of advanced non-small cell lung cancer in elderly patients or patients ineligible for platinum-based chemotherapy: a multicenter, randomized, phase II trial. J Thorac Oncol 2 (2007) 221-229
29. Monnerat C., Le Chevalier T., Kelly K., Obasaju C.K., Brahmer J., Novello S., et al. Phase II study of pemetrexed-gemcitabine combination in patients with advanced-stage non-small cell lung cancer. Clin Cancer Res 10 (2004) 5439-5446
30. Ma C.X., Nair S., Thomas S., Mandrekar S.J., Nikcevich D.A., Rowland K.M., et al. Randomized phase II trial of three schedules of pemetrexed and gemcitabine as front-line therapy for advanced non-small-cell lung cancer. J Clin Oncol 23 (2005) 5929-5937
31. Treat J., Bonomi P., McCleod M., Christiansen N.P., Mintzer D.M., Monberg M.J., et al. Administration of pemetrexed immediately following gemcitabine as front-line therapy in advanced non-small cell lung cancer: a phase II trial. Lung Cancer 53 (2006) 77-83
32. Ye Z., and Treat J.A. Meta-analysis of pemetrexed (P) plus gemcitabine (G) in first-line, advanced (adv) non-small cell lung cancer (NSCLC). J Clin Oncol 25 18S (2007) 685s [abstract 18015]
33. Clarke S.J., Boyer M.J., Millward M., Underhill C., Moylan E., Yip D., et al. A phase I/II study of pemetrexed and vinorelbine in patients with non-small cell lung cancer. Lung Cancer 49 (2005) 401-412
34. Manegold C., Gatzemeier U., von Pawel J., Pirker R., Malayeri R., Blatter J., et al. Front-line treatment of advanced non small cell lung cancer with MTA (LY231514, pemetrexed disodium, ALIMTA) and cisplatin: a multicenter phase II trial. Ann Oncol 11 (2000) 435-440
35. Shepherd F.A., Dancey J., Arnold A., Neville A., Rusthoven J., Johnson R.D., et al. Phase II study of pemetrexed disodium, a multitargeted antifolate, and cisplatin as first-line therapy in patients with advanced nonsmall cell lung carcinoma: a study of the National Cancer Institute of Canada Clinical Trials Group. Cancer 92 (2001) 595-600
36. Scagliotti G.V., Kortsik C., Dark G.G., Price A., Manegold C., Rosell R., et al. Pemetrexed combined with oxaliplatin or carboplatin as first-line treatment in advanced non-small cell lung cancer: a multicenter, randomized, phase II trial. Clin Can Res 11 (2005) 690-696
37. Zinner R.G., Fossella F.V., Gladish G.W., Glisson B.S., Blumenschein Jr. G.R., Papadimitrakopoulou V.A., et al. Phase II study of pemetrexed in combination with carboplatin in the first-line treatment of advanced nonsmall cell lung cancer. Cancer 104 (2005) 2449-2456
38. Peng G., Zinner R.G., Wang Y., Treat J., Monberg M., Obasaju C.K., et al. Comparison of patients outcomes stratified by histology among pemetrexed (P)-treated patients (pts) with stage IIIB/IV non-small cell lung cancer (NSCLC) in two phase II trials. J Clin Oncol 26 15S (2008) 447s [abstract 8096]
39. Gronberg B.H., Bremnes R., Flotten O., Amundsen T., Brunsvig P.Fr., Hjelde H.H., et al. Phase III study by the Norwegian Lung Cancer Study Group: pemetrexed plus carboplatin compared with gemcitabine plus carboplatin as first-line chemotherapy in advanced non-small-cell lung cancer. J Clin Oncol May 11 (2009) [Epub ahead of print]
40. Scagliotti G.V., Park K., Patil S., Rolski J., Goksel T., Martins R., et al. Survival without toxicity for cisplatin plus pemetrexed versus cisplatin plus gemcitabine in chemonaïve patients with advanced non-small cell lung cancer: a risk-benefit analysis of a large phase III study. Eur J Cancer May 25 (2009) [Epub ahead of print]
41. Orlando M., Lee J.S., Yang C., Simms L., and Park K. Efficacy of pemetrexed-cisplatin (PC) in East Asian patients (pts): subgroup analysis of a phase III study comparing PC versus gemcitabine-cisplatin (GC) in first-line treatment of advanced non-small cell lung cancer (NSCLC). J Clin Oncol 27 15S (2009) 418s [abstract 8045]
42. Grossi F., Aita M., Follador A., Defferrari C., Brianti A., Sinaccio G., et al. Sequential, alternating and maintenance/consolidation chemotherapy in advanced non-small cell lung cancer: a review of the literature. Oncologist 12 (2007) 451-464
43. Belani C.P., Brodowicz T., Ciuleanu T., Kim J.H., Krzakowski M., Laack E., et al. Maintenance pemetrexed (Pem) plus best supportive care (BSC) versus placebo (Plac) plus BSC: a randomized phase III study in advanced non-small cell lung cancer (NSCLC). J Clin Oncol 27 15S (2009) 806s [abstract CRA8000]
44. Jalal S., Waterhouse D., Edelman M., Nattam S., Ansari R., Koneru K., et al. Pemetrexed plus cetuximab in patients (pts) with recurrent non-small cell lung cancer (NSCLC): a phase I-IIa dose-ranging study from the Hoosier Oncology Group. J Clin Oncol 25 18S (2007) 433s [abstract 7698]
45. Adjei A.A., Mandrekar S.J., Dy G.K., Molina J.R., Adjei A.A., Gandara D.R., et al. A phase II second-line study of pemetrexed (pem) in combination with bevacizumab (bev) in patients with advanced non-small cell lung cancer (NSCLC): an NCCTG and SWOG study. J Clin Oncol 26 15S (2008) 443s [abstract 8080]
46. Patel J.D., Hensing T.A., Rademaker A., Hart E.M., Blum M.G., Milton D.T., et al. Phase II study of pemetrexed and carboplatin plus bevacizumab with maintenance pemetrexed and bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer. J Clin Oncol May 11 (2009) [Epub ahead of print]
47. Waples J.M., Auerbach M., Steis R., Boccia R.V., and Wiggans R.G. A phase II study of oxaliplatin and pemetrexed plus bevacizumab in advanced non-squamous non-small cell lung cancer (An International Oncology Network Study, #I-04-015). J Clin Oncol 26 15S (2008) 707s [abstract 19018]
48. Heist R.S., Fidias P., Huberman M., Ardman B., Sequist L.V., Temel J.S., et al. A phase II study of oxaliplatin, pemetrexed, and bevacizumab in previously treated advanced non-small cell lung cancer. J Thorac Oncol 3 (2008) 1153-1158
49. Casey E.M., Harb W., Bradford D., Bufill J., Nattam S., Patel J., et al. Randomized, double blind, multicenter, phase II study of pemetrexed (PEM), carboplatin (CARBO), bevacizumab (BEV) with enzastaurin (ENZ) or placebo (PBO) in chemotherapy-naive patients with stage IIIB/IV non-small cell lung cancer (NSCLC): Hoosier Oncology Group (HOG) LUN06-116. J Clin Oncol 27 15S (2009) 415S [abstract 8035]
50. Obasaju C.K., Raju R.N., Stinchcombe T., Couch L.S., Jotte R., Kocs D.M., et al. Final results of a randomized phase II trial of pemetrexed (P) + carboplatin (Cb) ± enzastaurin (E) versus docetaxel (D) + Cb as first-line treatment of patients (pts) with stage IIIB/IV non-small cell lung cancer (NSCLC). J Clin Oncol 27 15S (2009) 416s [abstract 8037]
51. Govindan R., Page N., Morgensztern D., Read W., Tierney R., Vlahiotis A., et al. Changing epidemiology of small-cell lung cancer in the United States over the last 30 years: analysis of the surveillance, epidemiologic, and end results database. J Clin Oncol 24 (2006) 4539-4544
52. Jackman D.M., and Johnson B.E. Small-cell lung cancer. Lancet 366 (2005) 1385-1396
53. Socinski M.A., Weissman C., Hart L.L., Beck J.T., Choksi J.K., Hanson J.P., et al. Randomized phase II trial of pemetrexed combined with either cisplatin or carboplatin in untreated extensive-stage small-cell lung cancer. J Clin Oncol 24 (2006) 4840-4847
54. Socinski MA, Smit EF, Lorigan P, Konduri K, Reck M, Szczesna A, et al. Phase III study of pemetrexed plus carboplatin (PC) versus etoposide and carboplatin (EC) in chemonaive patients (pts) with extensive-stage disease small cell lung cancer (ED-SCLC): interim results. http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=55&abstractID=100000.
55. Socinski M.A., Raju R.N., Neubauer N., Smith D.A., Richards D.A., Savin M., et al. Pemetrexed in relapsed small-cell lung cancer and the impact of shortened vitamin supplementation lead-in time: results of a phase II trial. J Thorac Oncol 3 (2008) 1308-1316
56. Jalal S., Ansari R., Govindan R., Bhatia S., Bruetman D., Fisher W., et al. Pemetrexed in second line and beyond small cell lung cancer: a Hoosier Oncology Group phase II study. J Thorac Oncol 4 (2009) 93-96
57. Gronberg B.H., Bremnes R.M., Aasebo U., Brunsvig P., Flotten O., Amundsen T., et al. A prospective phase II study: high-dose pemetrexed as second-line chemotherapy in small-cell lung cancer. Lung Cancer 63 (2009) 88-93
58. Ceppi P., Volante M., Ferrero A., Righi L., Rapa I., Rosas R., et al. Thymidylate synthase expression in gastroenteropancreatic and pulmonary neuroendocrine tumors. Clin Cancer Res 14 (2008) 1059-1064
59. Smit E.F., Socinski M.A., Mullaney B.P., Myrand S.P., Powell E., Lorigan P., et al. Pharmacogenomic analysis from a phase III study of pemetrexed plus carboplatin (PC) versus etoposide plus carboplatin (EC) in chemonaive patients (pts) with extensive-stage disease small cell lung cancer (ED-SCLC). J Clin Oncol 27 15S (2009) 414s [abstract 8030]